Shattuck Dividend Paid And Capex Coverage Ratio from 2010 to 2024

STTK Stock  USD 1.15  0.11  10.58%   
Shattuck Labs Dividend Paid And Capex Coverage Ratio yearly trend continues to be quite stable with very little volatility. Dividend Paid And Capex Coverage Ratio may rise above -189.6 this year. From the period between 2010 and 2024, Shattuck Labs, Dividend Paid And Capex Coverage Ratio regression line of its data series had sample variance of  4,308 and sample variance of  4,308. View All Fundamentals
 
Dividend Paid And Capex Coverage Ratio  
First Reported
2010-12-31
Previous Quarter
(199.58)
Current Value
(189.60)
Quarterly Volatility
65.63308327
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Shattuck Labs financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Shattuck Labs' main balance sheet or income statement drivers, such as Net Interest Income of 4.9 M, Interest Income of 4.9 M or Depreciation And Amortization of 4.2 M, as well as many indicators such as Price To Sales Ratio of 192, Dividend Yield of 0.0 or PTB Ratio of 2.2. Shattuck financial statements analysis is a perfect complement when working with Shattuck Labs Valuation or Volatility modules.
  
Check out the analysis of Shattuck Labs Correlation against competitors.
For more information on how to buy Shattuck Stock please use our How to buy in Shattuck Stock guide.

Latest Shattuck Labs' Dividend Paid And Capex Coverage Ratio Growth Pattern

Below is the plot of the Dividend Paid And Capex Coverage Ratio of Shattuck Labs over the last few years. It is Shattuck Labs' Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Shattuck Labs' overall financial position and show how it may be relating to other accounts over time.
Dividend Paid And Capex Coverage Ratio10 Years Trend
Slightly volatile
   Dividend Paid And Capex Coverage Ratio   
-44.63-46.30-7.21-8.14-199.58-189.60100%
       Timeline  

Shattuck Dividend Paid And Capex Coverage Ratio Regression Statistics

Arithmetic Mean(36.55)
Coefficient Of Variation(179.59)
Mean Deviation44.52
Median(5.86)
Standard Deviation65.63
Sample Variance4,308
Range194
R-Value(0.65)
Mean Square Error2,689
R-Squared0.42
Significance0.01
Slope(9.51)
Total Sum of Squares60,308

Shattuck Dividend Paid And Capex Coverage Ratio History

2024 -189.6
2023 -199.58
2022 -8.14
2021 -7.21
2020 -46.3
2019 -44.63

About Shattuck Labs Financial Statements

Shattuck Labs investors utilize fundamental indicators, such as Dividend Paid And Capex Coverage Ratio, to predict how Shattuck Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Dividend Paid And Capex Coverage Ratio(199.58)(189.60)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Shattuck Labs is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Shattuck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Shattuck Labs Stock. Highlighted below are key reports to facilitate an investment decision about Shattuck Labs Stock:
Check out the analysis of Shattuck Labs Correlation against competitors.
For more information on how to buy Shattuck Stock please use our How to buy in Shattuck Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Shattuck Labs. If investors know Shattuck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Shattuck Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.53)
Revenue Per Share
0.088
Quarterly Revenue Growth
7.045
Return On Assets
(0.40)
Return On Equity
(0.68)
The market value of Shattuck Labs is measured differently than its book value, which is the value of Shattuck that is recorded on the company's balance sheet. Investors also form their own opinion of Shattuck Labs' value that differs from its market value or its book value, called intrinsic value, which is Shattuck Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Shattuck Labs' market value can be influenced by many factors that don't directly affect Shattuck Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Shattuck Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Shattuck Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Shattuck Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Trending Assets

CCCC
C4 Therapeutics
3.95  0.10  2.60 
PRLD
Prelude Therapeutics
1.30  0.41  46.07 
STOK
Stoke Therapeutics
11.68  0.38  3.36 
IPSC
Century Therapeutics
1.10  0.05  4.76 
CSBR
Champions Oncology
7.51  -0.04  -0.53 
PMVP
Pmv Pharmaceuticals
1.50  0.01  0.67 
FHTX
Foghorn Therapeutics
4.98  0.07  1.43 
ELYM
Eliem Therapeutics
3.09  -0.06  -1.9 
PRDS
Pardes Biosciences
2.14  0.01  0.47 
KYMR
Kymera Therapeutics
40.66  1.52  3.88 
GLUE
Monte Rosa Therapeutics
6.93  0.42  6.45 
NRIX
Nurix Therapeutics
19.83  -0.21  -1.05 
News Freq…Investor S…